Cidp clinical trials

Explore recruiting cidp clinical trials.

Recruiting cidp studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cidp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sweden, Spain, Norway, Germany, Denmark, Poland +8 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

Poland, Germany, France, Spain, Italy, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Czechia, Denmark, Poland, Slovenia, Netherlands, Austria +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Belgium, Denmark, Italy, Romania, Germany, Slovakia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)

Portugal, Poland, Belgium, Hungary, Czechia, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Rituximab-induced remission in CIDP (ReCIX study)

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cidp trials by city

Cidp in Toronto Cidp in Vancouver Cidp in Montreal Cidp in Calgary Cidp in Edmonton Cidp in Ottawa Cidp in Winnipeg Cidp in Quebec City Cidp in Hamilton Cidp in Kitchener Cidp in London Cidp in Halifax Cidp in New York Cidp in Los Angeles Cidp in Chicago Cidp in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease